August 27, 2016 9:46 AM ET

Biotechnology

Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

55 Employees

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $472.8K
Senior Advisor
Age: 58
Total Annual Compensation: $291.2K
Compensation as of Fiscal Year 2015.

aTyr Pharma Inc. Key Developments

aTyr Pharma Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016

aTyr Pharma Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported loss from operations of $15,433,000 against $10,898,000 a year ago. Net loss was $15,383,000 against $11,080,000 a year ago. Net loss attributable to common stockholders was $15,383,000 or $0.65 per share basic and diluted against $11,095,000 or $0.74 per share basic and diluted a year ago. For the six months, the company reported loss from operations of $31,548,000 against $19,820,000 a year ago. Net loss was $31,470,000 against $20,151,000 a year ago. Net loss attributable to common stockholders was $31,470,000 or $1.33 per share basic and diluted against $20,166,000 or $2.53 per share basic and diluted a year ago.

aTyr Pharma Inc. Presents at 2016 Wells Fargo San Francisco Biotech Corporate Access Day, Jul-28-2016

aTyr Pharma Inc. Presents at 2016 Wells Fargo San Francisco Biotech Corporate Access Day, Jul-28-2016 . Venue: Hotel Vitale, San Francisco, California, United States.

aTyr Pharma Inc.(NasdaqGS:LIFE) dropped from Russell 2000 Index

aTyr Pharma Inc. has been removed from Russell 2000 Index.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact aTyr Pharma Inc., please visit www.atyrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.